•Journal•ISSN: 1083-8791
Biology of Blood and Marrow Transplantation
Elsevier BV
About: Biology of Blood and Marrow Transplantation is an academic journal published by Elsevier BV. The journal publishes majorly in the area(s): Transplantation & Hematopoietic stem cell transplantation. It has an ISSN identifier of 1083-8791. It is also open access. Over the lifetime, 7567 publications have been published receiving 204645 citations. The journal is also known as: TCT.
Topics: Transplantation, Hematopoietic stem cell transplantation, Graft-versus-host disease, Stem cell, Population
Papers published on a yearly basis
Papers
More filters
Vanderbilt University Medical Center1, Medical University of Vienna2, University of Minnesota3, National Institutes of Health4, University of Regensburg5, Mayo Clinic6, Brigham and Women's Hospital7, Fred Hutchinson Cancer Research Center8, BC Cancer Agency9, State University of Campinas10, Stanford University11, University of Michigan12, Harvard University13, Johns Hopkins University School of Medicine14
TL;DR: The 2014 NIH consensus maintains the framework of the prior consensus with further refinement based on new evidence, and focuses attention on the causes of organ-specific abnormalities to chronic GVHD.
4,122 citations
Veterans Health Administration1, Medical University of Vienna2, University of Minnesota3, University of Regensburg4, National Institutes of Health5, Mayo Clinic6, Harvard University7, Fred Hutchinson Cancer Research Center8, University of British Columbia9, Stanford University10, University of Michigan11, Johns Hopkins University12
TL;DR: In this article, the authors proposed a new clinical scoring system (0-3) that describes the extent and severity of chronic graft-versus-host disease for each organ or site at any given time, taking functional impact into account.
2,883 citations
TL;DR: Changes include the recommendations for PCV rather than PPSV-23 for pneumococcal vaccination, starting some vaccinations earlier post-transplant, and the addition of recommendations for Varivax, HPV vaccine, and (the non-use of) Zostavax vaccine are included.
1,434 citations
TL;DR: Nonmyeloablative HLA-haploidentical BMT with posttransplantation Cy is associated with acceptable rates of fatal graft failure and severe aGVHD or cGVHD, and there was a trend toward a lower risk of extensive chronic GVHD (cGVHD) among recipients of 2 versus 1 dose of posttrans transplantation Cy.
1,420 citations
University of Virginia1, Memorial Sloan Kettering Cancer Center2, Washington University in St. Louis3, Fred Hutchinson Cancer Research Center4, National Institutes of Health5, Harvard University6, Novartis7, Seattle Children's8, University of Pennsylvania9, University College London10, Center for International Blood and Marrow Transplant Research11, University of Miami12, University of Texas MD Anderson Cancer Center13
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
1,403 citations